What question did this study set out to answer?

To explore the role of the MAP2K1/ERK pathway in hypertrophic scars and evaluate the effectiveness of SCH772984-loaded microneedles.

March 13, 2026ACS Biomaterials Science & Engineering0 citations

View Full Paper

Dissolvable Microneedle Arrays Loaded with SCH772984 Targeting the MAPK/ERK Pathway to Inhibit Abnormal Vascular Proliferation in Hypertrophic Scars

SYS Samuel Yang SYS Samuel Yang JYJie Yang

Key Points

To explore the role of the MAP2K1/ERK pathway in hypertrophic scars and evaluate the effectiveness of SCH772984-loaded microneedles.
Investigated the role of the MAP2K1/ERK pathway in hypertrophic scars.
Developed dissolvable microneedle arrays (DMNA) loaded with SCH772984.
Assessed the transdermal delivery system for its therapeutic potential.
Demonstrated the involvement of the MAP2K1/ERK pathway in angiogenesis of hypertrophic scars.
Showed that SCH772984 effectively inhibited vascular proliferation in the scar model.
Confirmed that the DMNA platform is a promising method for transdermal drug delivery.

Abstract

This study highlights the critical role of the MAP2K1/ERK pathway in mediating HS angiogenesis. Furthermore, the SCH772984-loaded DMNA platform described here is a promising and minimally invasive transdermal therapeutic approach for the clinical management of HS.

Demander à l'IA

Bookmark

View Full Paper

Demander à l'IA

Bookmark

View Full Paper

Dissolvable Microneedle Arrays Loaded with SCH772984 Targeting the MAPK/ERK Pathway to Inhibit Abnormal Vascular Proliferation in Hypertrophic Scars

Key Points

Abstract

Cite This Study